Predictive Clinical and Biological Parameters in Gynecological Cancer (GC-BIO)
Primary Purpose
Ovarian Cancer, Endometrium Cancer, Cervix Cancer
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
gynecological cancer
Sponsored by
About this trial
This is an interventional basic science trial for Ovarian Cancer focused on measuring ovarian, endometrium, cervix cancer
Eligibility Criteria
Inclusion Criteria:
- gynecological cancer suspicion
- age > 18
- signed informed consent
Exclusion Criteria:
- emergency
Exclusion criteria after histological exam Any diagnosis that is not a gynecological cancer (ovarian, cervix, endometrium).
Sites / Locations
- Institut Paoli CalmettesRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
gynecological cancer
Arm Description
blood and tumor samples
Outcomes
Primary Outcome Measures
molecular alteration in gynecological cancer
gene expression level
Secondary Outcome Measures
relation between molecular alteration and clinical and histological characteristics
hazard ratio between molecular alteration and clinico-histological characteristics
Full Information
NCT ID
NCT01977274
First Posted
October 30, 2013
Last Updated
June 30, 2020
Sponsor
Institut Paoli-Calmettes
1. Study Identification
Unique Protocol Identification Number
NCT01977274
Brief Title
Predictive Clinical and Biological Parameters in Gynecological Cancer
Acronym
GC-BIO
Official Title
Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Recruiting
Study Start Date
December 2013 (undefined)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2033 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Paoli-Calmettes
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cancer, Endometrium Cancer, Cervix Cancer
Keywords
ovarian, endometrium, cervix cancer
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
gynecological cancer
Arm Type
Experimental
Arm Description
blood and tumor samples
Intervention Type
Other
Intervention Name(s)
gynecological cancer
Intervention Description
blood and tumor samples
Primary Outcome Measure Information:
Title
molecular alteration in gynecological cancer
Description
gene expression level
Time Frame
average of 4 weeks after diagnosis
Secondary Outcome Measure Information:
Title
relation between molecular alteration and clinical and histological characteristics
Description
hazard ratio between molecular alteration and clinico-histological characteristics
Time Frame
up to 10 years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
gynecological cancer suspicion
age > 18
signed informed consent
Exclusion Criteria:
- emergency
Exclusion criteria after histological exam Any diagnosis that is not a gynecological cancer (ovarian, cervix, endometrium).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dominique GENRE, MD
Phone
33491223778
Email
drci.up@ipc.unicancer.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Margot BERLINE, MSc, MBA
Phone
33491223778
Email
drci.up@ipc.unicancer.fr
Facility Information:
Facility Name
Institut Paoli Calmettes
City
Marseille
ZIP/Postal Code
13 009
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominique GENRE, MD
Phone
33491223778
Email
drci.up@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Margot BERLINE, MSc, MBA
Phone
33491223778
Email
drci.up@ipc.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Eric LAMBAUDIE, MD
12. IPD Sharing Statement
Links:
URL
http://www.institutpaolicalmettes.fr
Description
official web site of the sponsor
Learn more about this trial
Predictive Clinical and Biological Parameters in Gynecological Cancer
We'll reach out to this number within 24 hrs